FDA Approves Expanded Age Indication for RSV Vaccine
The FDA has approved expanded use of Arexvy, an RSV vaccine, for those aged 18-49 at increased LRTD risk.

FDA warns Novo Nordisk broke safety reporting rules
Federal regulators have warned the maker of Ozempic and Wegovy that it failed to report possible drug side effects to the government.




